Cargando…

Exploring common genetic contributors to neuroprotection from amyloid pathology

Preclinical Alzheimer’s disease describes some individuals who harbour Alzheimer’s pathologies but are asymptomatic. For this study, we hypothesized that genetic variation may help protect some individuals from Alzheimer’s-related neurodegeneration. We therefore conducted a genome-wide association s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seto, Mabel, Mahoney, Emily R., Dumitrescu, Logan, Ramanan, Vijay K., Engelman, Corinne D., Deming, Yuetiva, Albert, Marilyn, Johnson, Sterling C., Zetterberg, Henrik, Blennow, Kaj, Vemuri, Prashanthi, Jefferson, Angela L., Hohman, Timothy J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006043/ https://www.ncbi.nlm.nih.gov/pubmed/35425899 http://dx.doi.org/10.1093/braincomms/fcac066

Ejemplares similares

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
por: Seto, Mabel, et al.
Publicado: (2021)

CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
por: Dong, Ruocheng, et al.
Publicado: (2023)

Apolipoprotein E moderates the association between Non-APOE Polygenic Risk Score for Alzheimer’s Disease and Aging on Preclinical Cognitive Function
por: Xu, Yuexuan, et al.
Publicado: (2023)

Effect of Pathway-specific Polygenic Risk Scores for Alzheimer’s Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals
por: Xu, Yuexuan, et al.
Publicado: (2023)

Telomere length associations with cognition depend on Alzheimer's disease biomarkers
por: Mahoney, Emily R., et al.
Publicado: (2019)

APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease
por: Hohman, Timothy J., et al.
Publicado: (2017)

Evaluation of Sex-Aware PrediXcan Models for Predicting Gene Expression
por: Mahoney, Emily, et al.
Publicado: (2022)

TREM2 gene expression associations with Alzheimer’s disease neuropathology are region-specific: implications for cortical versus subcortical microglia
por: Winfree, Rebecca L., et al.
Publicado: (2023)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism
por: Mattsson, Niklas, et al.
Publicado: (2010)

Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics
por: Varatharajah, Yogatheesan, et al.
Publicado: (2019)

Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology
por: Tanabe, Sean, et al.
Publicado: (2020)

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
por: Selnes, Per, et al.
Publicado: (2010)

The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease
por: Vogt, Nicholas M., et al.
Publicado: (2018)

Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations
por: Panyard, Daniel J., et al.
Publicado: (2021)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Tetramodal Chemical Imaging Delineates the Lipid–Amyloid Peptide Interplay at Single Plaques in Transgenic Alzheimer’s Disease Models
por: Ge, Junyue, et al.
Publicado: (2023)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
por: van Westen, Danielle, et al.
Publicado: (2016)

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
por: Dansson, Hákon Valur, et al.
Publicado: (2021)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

The accuracy and robustness of plasma biomarker models for amyloid PET positivity
por: Benedet, Andréa L., et al.
Publicado: (2022)

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures
por: Mielke, Michelle M., et al.
Publicado: (2019)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

The relationship between white matter microstructure and self-perceived cognitive decline
por: Archer, Derek B., et al.
Publicado: (2021)

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
por: Voevodskaya, Olga, et al.
Publicado: (2016)

Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer’s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry
por: Kaya, Ibrahim, et al.
Publicado: (2016)

Blood‐brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein‐β in patients with subcortical small‐vessel disease
por: Kettunen, Petronella, et al.
Publicado: (2022)

Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later
por: Nägga, Katarina, et al.
Publicado: (2018)

Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study
por: Pomara, Nunzio, et al.
Publicado: (2022)

Decreased levels of soluble amyloid β-protein precursor and β-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus
por: Trysberg, Estelle, et al.
Publicado: (2004)

Alzheimer’s disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals
por: Pettigrew, Corinne, et al.
Publicado: (2023)

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
por: Palmqvist, Sebastian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l6i4j5mapirj5qgb84i6jvehsp